OTLC — Oncotelic Therapeutics Income Statement
0.000.00%
- $11.79m
- $23.91m
- $0.07m
- 20
- 27
- 52
- 24
Annual income statement for Oncotelic Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1.74 | 0 | 0 | 0.07 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6.08 | 9.67 | 8.81 | 9.98 | 7.09 |
Operating Profit | -6.08 | -7.93 | -8.81 | -9.98 | -7.02 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.64 | -9.97 | -10.5 | 4.68 | -8.21 |
Net Income After Taxes | -6.64 | -9.97 | -10.5 | 4.68 | -8.21 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -6.64 | -9.5 | -9.39 | 5.09 | -7.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.64 | -9.5 | -9.39 | 5.09 | -7.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.081 | -0.104 | -0.032 | 0.021 | -0.004 |